Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
BioAge Labs, Inc. - Common Stock
(NQ:
BIOA
)
23.86
+0.87 (+3.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about BioAge Labs, Inc. - Common Stock
Prediction: These 2 Stocks Could Soar in 2025
October 17, 2024
The key word here is "could."
Via
The Motley Fool
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
October 13, 2024
The future of the weight loss market might not revolve around GLP-1 drugs.
Via
The Motley Fool
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
October 12, 2024
BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
October 07, 2024
One of these businesses is a risky play, but the other is very likely to succeed.
Via
The Motley Fool
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October
October 05, 2024
There's a chance that its lead candidate could become one of the top drugs ever.
Via
The Motley Fool
This IPO Biotech Stock Could Be the Next Eli Lilly
October 03, 2024
BioAge has its eyes on a handful of truly gargantuan markets.
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
Obesity Drug Developer BioAge Makes Nasdaq Debut
September 29, 2024
Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead obesity drug further into clinical trials.
Via
Talk Markets
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
September 26, 2024
The company is working on a drug that mimics apelin, which is released following exercise.
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.